Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers
News
Telix Pharmaceuticals and Atlab Pharma are working together to develop and possibly market huJ591, a monoclonal antibody to be used in radioimmunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more